Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alnylam Pharmaceuticals, Inc., BeOne Medicines AG or BeOne Medicines AG because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG compare based on key financial metrics to determine which better meets your investment needs.

About Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Latest Biotechnology and Alnylam Pharmaceuticals, Inc., BeOne Medicines AG Stock News

As of August 21, 2026, Alnylam Pharmaceuticals, Inc. had a $31.6 billion market capitalization, compared to the Biotechnology median of $292.6 million. Alnylam Pharmaceuticals, Inc.’s stock is down 40.6% in 2026, up 3.3% in the previous five trading days and down 48.46% in the past year.

Currently, Alnylam Pharmaceuticals, Inc.’s price-earnings ratio is 42.0. Alnylam Pharmaceuticals, Inc.’s trailing 12-month revenue is $4.8 billion with a 16.1% net profit margin. Year-over-year quarterly sales growth most recently was 66.8%. Analysts expect adjusted earnings to reach $8.915 per share for the current fiscal year. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.

As of August 21, 2026, BeOne Medicines AG had a $42.6 billion market cap, putting it in the 92nd percentile of all stocks. BeOne Medicines AG’s stock is up 23.3% in 2026, up 7.8% in the previous five trading days and up 21.06% in the past year.

Currently, BeOne Medicines AG’s price-earnings ratio is 67.0. BeOne Medicines AG’s trailing 12-month revenue is $6.1 billion with a 10.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.6%. Analysts expect adjusted earnings to reach $7.598 per share for the current fiscal year. BeOne Medicines AG does not currently pay a dividend.

How We Compare Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG Growth Grades

Company	Ticker	Growth
Alnylam Pharmaceuticals, Inc.	ALNY	D
BeOne Medicines AG	ONC	D
BeOne Medicines AG	ONC	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alnylam Pharmaceuticals, Inc. has a Growth Score of 32, which is Weak. BeOne Medicines AG has a Growth Score of 30, which is Weak. BeOne Medicines AG has a Growth Score of 30, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Alnylam Pharmaceuticals, Inc., BeOne Medicines AG or BeOne Medicines AG has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Alnylam Pharmaceuticals, Inc., BeOne Medicines AG or BeOne Medicines AG is the better investment when it comes to sustainable growth.

Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG’s Quality Grades

Company	Ticker	Quality
Alnylam Pharmaceuticals, Inc.	ALNY	A
BeOne Medicines AG	ONC	B
BeOne Medicines AG	ONC	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Alnylam Pharmaceuticals, Inc. has a Quality Score of 86, which is Very Strong. BeOne Medicines AG has a Quality Score of 76, which is Strong. BeOne Medicines AG has a Quality Score of 76, which is Strong.

The Quality Grade Winner: Alnylam Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Alnylam Pharmaceuticals, Inc. has a better overall quality grade than BeOne Medicines AG. For investors who are looking for companies with higher quality than others in the same industry, Alnylam Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG’s Momentum Grades

Company	Ticker	Momentum
Alnylam Pharmaceuticals, Inc.	ALNY	F
BeOne Medicines AG	ONC	B
BeOne Medicines AG	ONC	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Alnylam Pharmaceuticals, Inc. has a Momentum Score of 11, which is Very Weak. BeOne Medicines AG has a Momentum Score of 66, which is Strong. BeOne Medicines AG has a Momentum Score of 66, which is Strong.

The Momentum Grade Winner: BeOne Medicines AG

As you can clearly see from the Momentum Grade breakdown above, BeOne Medicines AG is considered to have stronger momentum compared to Alnylam Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, BeOne Medicines AG could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG Grades

In addition to Growth, Momentum and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alnylam Pharmaceuticals, Inc., BeOne Medicines AG or BeOne Medicines AG Stock?

Overall, Alnylam Pharmaceuticals, Inc. stock has a Growth Score of 32, Momentum Score of 11 and Quality Score of 86.

BeOne Medicines AG stock has a Growth Score of 30, Momentum Score of 66 and Quality Score of 76.

BeOne Medicines AG stock has a Growth Score of 30, Momentum Score of 66 and Quality Score of 76.

Comparing Alnylam Pharmaceuticals, Inc., BeOne Medicines AG and BeOne Medicines AG’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.